top of page

Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

- First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community- - Commenced exclusive distribution of SIVEXTRO in the U.S. on April 12, 2021 and moving forward will record 100% of net product sales of SIVEXTRO in results of operations-

- Conference call today at 4:30 p.m. Eastern TimeCreate a blog post subtitle that summarizes your post in a few short, punchy sentences and entices your audience to continue reading.

Recent Posts

See All


bottom of page